- Home
- PULM vs LPCN Comparison
PULM vs LPCN Comparison
Compare PULM & LPCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PULM
- LPCN
- Stock Information
- Founded
- PULM 2003
- LPCN 1997
- Country
- PULM United States
- LPCN United States
- Employees
- PULM N/A
- LPCN N/A
- Industry
- PULM Biotechnology: Pharmaceutical Preparations
- LPCN Biotechnology: Pharmaceutical Preparations
- Sector
- PULM Health Care
- LPCN Health Care
- Exchange
- PULM Nasdaq
- LPCN Nasdaq
- Market Cap
- PULM 18.3M
- LPCN 16.1M
- IPO Year
- PULM N/A
- LPCN N/A
- Fundamental
- Price
- PULM $4.89
- LPCN $2.85
- Analyst Decision
- PULM
- LPCN Strong Buy
- Analyst Count
- PULM 0
- LPCN 2
- Target Price
- PULM N/A
- LPCN $9.00
- AVG Volume (30 Days)
- PULM 9.6K
- LPCN 16.6K
- Earning Date
- PULM 11-07-2025
- LPCN 11-06-2025
- Dividend Yield
- PULM N/A
- LPCN N/A
- EPS Growth
- PULM N/A
- LPCN N/A
- EPS
- PULM N/A
- LPCN N/A
- Revenue
- PULM $369,000.00
- LPCN $4,208,119.00
- Revenue This Year
- PULM N/A
- LPCN N/A
- Revenue Next Year
- PULM $134.88
- LPCN N/A
- P/E Ratio
- PULM N/A
- LPCN N/A
- Revenue Growth
- PULM N/A
- LPCN N/A
- 52 Week Low
- PULM $1.96
- LPCN $2.68
- 52 Week High
- PULM $10.40
- LPCN $6.17
- Technical
- Relative Strength Index (RSI)
- PULM 45.65
- LPCN 39.71
- Support Level
- PULM $4.70
- LPCN $2.87
- Resistance Level
- PULM $5.19
- LPCN $3.08
- Average True Range (ATR)
- PULM 0.15
- LPCN 0.10
- MACD
- PULM 0.07
- LPCN 0.00
- Stochastic Oscillator
- PULM 44.44
- LPCN 0.00
About PULM Pulmatrix Inc.
Pulmatrix Inc is a biopharmaceutical company that has focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with important unmet medical needs using its patented dry powder delivery technology, iSPERSE. Its pipeline of clinical assets includes PUR3100 for the treatment of acute migraine, PUR1800 for the treatment of acute exacerbations of chronic obstructive pulmonary disease (AECOPD), and PUR1900 for the treatment of ABPA in patients with asthma and in patients with cystic fibrosis (CF).
About LPCN Lipocine Inc.
Lipocine Inc is a clinical-stage biopharmaceutical company, that is engaged in research and development for the delivery of drugs using its proprietary delivery technology. Its principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its drug candidates or it develops drug candidates on behalf of or in collaboration with corporate partners. The company's product TLANDO is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, TLANDO, TLANDO XR, LPCN 1148, LPCN 1107, LPCN 1154, and LIP'RAL7 Technology. The Company has a single reportable segment, research, and development for the delivery of drugs using its proprietary delivery technology.